Search results
Showing 496 to 510 of 554 results for end of life care
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway.
Evidence-based recommendations on adalimumab, etanercept, infliximab and abatacept for adults with moderate rheumatoid arthritis who have tried conventional DMARDs but they have not worked.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.
Digital self-help for eating disorders: early value assessment (HTG768)
Early value assessment (EVA) guidance on digital self-help for eating disorders.
This guideline covers road-traffic-related air pollution and its links to ill health. It aims to improve air quality and so prevent a range of health conditions and deaths.
Early value assessment (EVA) guidance on digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people.
Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults.
Show all sections
Molecular testing strategies for Lynch syndrome in people with colorectal cancer (HTG430)
Evidence-based recommendations on using immunohistochemistry or microsatellite instability testing to guide further testing for Lynch syndrome in people with colorectal cancer.
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.
View recommendations for TA340Show all sections
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)
Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease.
Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.
This guideline covers complex rehabilitation needs after traumatic injury, including assessment and goal setting, rehabilitation plans and programmes, physical, psychological and cognitive rehabilitation, rehabilitation for specific injuries, coordination of rehabilitation in hospital, at discharge and in the community, and commissioning and organising rehabilitation services.
Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA795)
Evidence-based recommendations on ibrutinib (Imbruvica) for Waldenstrom’s macroglobulinaemia in adults who have had at least 1 previous therapy.
Early value assessment (EVA) guidance on KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication.